News for PharmaCyte Biotech, Inc. (PMCB)

As per SNS Insider research, Growing Geriatric Population, Emerging Chemotherapies, and Increased Healthcare Investments in Asia-Pacific and Middle East...

In this article, we will be analyzing the age structures globally while covering the 30 countries with the lowest median age in the world.

Increasing prevalence of target disorders, innovative drug delivery systems to treat chronic illnesses and technological advances contribute to live cell...

Incorporation of Microfluidics and 3D Printing Techniques Has Enhanced the Accuracy and Scalability of Live Cell Encapsulation. A rise in demand for...

According to Fortune Business Insights, The global pancreatic cancer treatment market size was worth USD 2.15 billion in 2021. The market valuation is...

Meta Platforms, Inc. announced a whopping $40 billion share repurchase program.

The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET)..

The rising alcohol and tobacco consumption prevalence contribute to the growth of pancreatic cancer market. The increased emphasis on R&D in molecular...

Read Head-To-Head Comparison: PharmaCyte Biotech (PMCB) & Its Peers at ETF Daily News

Read Analyzing Agenus (NASDAQ:AGEN) and PharmaCyte Biotech (OTCMKTS:PMCB) at ETF Daily News

Wilmington, Delaware, United States: The pancreas is anatomically so placed that any growth here affects multiple organs like the stomach, gall bladder and intestines.

Read Equities Research Analysts’ Downgrades for May 18th (APO, APPF, AZN, BYCBF, CARR, CCBG, CENX, CF, CLH, CRH) at ETF Daily News

/PRNewswire/ -- The "COVID-19 Nucleic Acid Amplification Tests (NAATs) - Medical Devices Pipeline Product Landscape, 2021" report has been added to...

Gainers Trillium Therapeutics Inc. (NASDAQ:TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pf...

PharmaCyte Biotech, Inc. , a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today... | August 16, 2021

LAGUNA HILLS, Calif., August 16, 2021--PharmaCyte releases statement on Nasdaq uplisting and current business focus.

PharmaCyte Biotech, Inc. PMCB (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.04%